Cytotoxic therapy

Abstract From the Canadian patent

Anticancer antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity especially to hematopoistic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agens can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.